Results 91 to 100 of about 2,723 (121)
<i>Proprotein Convertase Subtilisin</i>/<i>Kexin Type 9</i> (<i>PCSK9</i>) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]
Int J Mol SciWoźniak E +6 more
europepmc +1 more source
Treatment pathways of lipid-lowering therapies in Germany 2016-2022. [PDF]
Clin Res CardiolKatzmann JL +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
[Anticholesteremic agents in children].
Therapie, 2003The treatment of hypercholesterolaemia in children is often discussed as part of the primary prevention strategy for premature coronary disease in adults. Cholesterol-lowering drugs are appropriate in children with hereditary autosomal dominant diseases such as familial hypercholesterolaemia, familial Apo B100 deficiency, or combined familial ...
openaire +1 more source
Risk scoring for the primary prevention of cardiovascular disease
The Cochrane Library, 2021Mark Huffman +2 more
exaly
[Contribution to anticholesteremic agents?].
Ugeskrift for laeger, 1998P, Astrup, F, Gyntelberg
openaire +1 more source
[Anticholesteremic agents and cholelithiasis].
Nihon rinsho. Japanese journal of clinical medicine, 1978G, Kajiyama +3 more
openaire +1 more source
[Clinical evaluation of anticholesteremic agents].
Naika. Internal medicine, 1968T, Kimura, H, Kudo
openaire +1 more source
[Effects and side-effects of anticholesteremic agents].
Nihon rinsho. Japanese journal of clinical medicine, 1969Y, Yoshitoshi, C, Naito
openaire +1 more source
[Arteriosclerosis with special reference to anticholesteremic agents].
Naika. Internal medicine, 1970M, Murakami +4 more
openaire +1 more source